VKTX insider trading
NasdaqCM HealthcareViking Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Company website: www.vikingtherapeutics.com
VKTX insider activity at a glance
FilingIQ tracks 344 insider transactions for VKTX in filings since May 5, 2015. The most recent transaction is dated Aug 1, 2026.
Across the full history, 12 open-market purchases
and 112 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VKTX insider trades is 59.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VKTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for VKTX?
- FilingIQ tracks 344 Form 4 insider transactions for VKTX (Viking Therapeutics, Inc.), covering filings from May 5, 2015 onwards. 7 of those are dated within the last 90 days.
- Are VKTX insiders net buyers or net sellers?
- Across the full Form 4 history for VKTX, 12 transactions (3%) were open-market purchases and 112 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VKTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is VKTX in?
- Viking Therapeutics, Inc. (VKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.92B.
Methodology & sources
Every VKTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.